Who
Margaret A. Horn
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Revolution Medicines; Director, Sangamo Therapeutics; SVP, General Counsel, Kosan Biosciences.
In numbers
- Trades disclosed
- 156
- Buys
- 0
- Sells
- 41
- Bought
- $0
- Sold
- $63.3M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 3 Jan 2006
- Last trade
- 16 Sep 2026
- Last filed
- 18 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Sep 2026filed 18 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $15K76 at $195.01 | filing |
| 16 Sep 2026filed 18 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $975K4,891 at $199.30 | filing |
| 16 Sep 2026filed 18 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $15K76 at $195.01 | filing |
| 16 Sep 2026filed 18 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $975K4,891 at $199.30 | filing |
| 17 Jun 2026filed 17 Jun 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code M | —573 at $0.00 | filing |
| 17 Jun 2026filed 17 Jun 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,302 at $0.00 | filing |
| 17 Jun 2026filed 17 Jun 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,725 at $0.00 | filing |
| 17 Jun 2026filed 17 Jun 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code M | —573 at $0.00 | filing |
| 17 Jun 2026filed 17 Jun 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,302 at $0.00 | filing |
| 17 Jun 2026filed 17 Jun 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,725 at $0.00 | filing |
| 17 Jun 2026filed 17 Jun 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code M | $23K573 at $40.74 | filing |
| 17 Jun 2026filed 17 Jun 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code M | $98K3,302 at $29.80 | filing |
| 17 Jun 2026filed 17 Jun 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code M | $682K25,725 at $26.50 | filing |
| 17 Jun 2026filed 17 Jun 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $4.7M29,600 at $160.12 | filing |
| 17 Jun 2026filed 17 Jun 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code M | $23K573 at $40.74 | filing |
| 17 Jun 2026filed 17 Jun 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code M | $98K3,302 at $29.80 | filing |
| 17 Jun 2026filed 17 Jun 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code M | $682K25,725 at $26.50 | filing |
| 17 Jun 2026filed 17 Jun 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $4.7M29,600 at $160.12 | filing |
| 15 Jun 2026filed 17 Jun 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code M | $633K15,546 at $40.74 | filing |
| 15 Jun 2026filed 17 Jun 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code M | —44,854 at $0.00 | filing |
News
Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026RVMD · manilatimes.net · 23 Oct 2026Contrasting Revolution Medicines (NASDAQ:RVMD) and Agios Pharmaceuticals (NASDAQ:AGIO)RVMD · themarketsdaily.com · 22 Oct 20263,946 Shares of Revolution Medicines, Inc. $RVMD Acquired by Vontobel Holding Ltd.RVMD · dailypolitical.com · 21 Oct 2026
0 headlines in the last 90 days name Margaret A. Horn; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.